Apr 8, 2018 | Featured, Research News, Technology Updates
Eli Lilly ponies up $63M for Sigilon’s diabetes cell therapies, according to Amirah Al Adrus of FierceBiotech.com, 4 April 2018. Eli Lilly is continuing its push into new diabetes products, paying $63 million up front to get its hands on Sigilon Therapeutics’...